Atypical Ductal Hyperplasia and Those Boarding on Ductal Carcinoma in Situ Should be Included in the Active Surveillance Clinical Trials

被引：0

作者：

Khoury, Thaer ^{[1
]}

Jabbour, Nashwan ^{[2
]}

Peng, Xuan ^{[3
]}

Yan, Li ^{[1
]}

Quinn, Marie ^{[1
]}

机构：

[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[2] Roswell Pk Canc Inst, Lexington, KY USA

[3] Roswell Pk Canc Inst, Snyder, NY USA

来源：

MODERN PATHOLOGY | 2019年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

179

引用

页数：1

共 50 条

[31] Analysis of active surveillance as a treatment modality in ductal carcinoma in situ
Fan, Betty
Pardo, Jaime A.
Alapati, Amulya
Hopewood, Peter
Virk, Zain Mohammad
James, Ted A.
BREAST JOURNAL, 2020, 26 (06): : 1221 - 1226
[32] Challenges of conducting active surveillance for ductal carcinoma in situ (DCIS)
Lynch, Thomas
CANCER PREVENTION RESEARCH, 2022, 15 (12)
[33] COMPARATIVE ULTRASTRUCTURE OF ATYPICAL DUCTAL HYPERPLASIA, INTRADUCTAL CARCINOMA, AND INFILTRATING DUCTAL CARCINOMA OF BREAST
GOLDENBERG, VE
GOLDENBERG, NS
SOMMERS, SC
CANCER, 1969, 24 (06) : 1152 - +
[34] Chemoprevention uptake among women with atypical hyperplasia, lobular and ductal carcinoma in situ
Coe, A. M.
Trivedi, M. S.
Vanegas, A.
Kukafka, R.
Crew, K. D.
CANCER RESEARCH, 2017, 77
[35] Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ
Trivedi, Meghna S.
Coe, Austin M.
Vanegas, Alejandro
Kukafka, Rita
Crew, Katherine D.
CANCER PREVENTION RESEARCH, 2017, 10 (08) : 434 - 441
[36] Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ
Martinez, Anthony P.
Cohen, Cynthia
Hanley, Krisztina Z.
Li, Xiaoxian
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (07) : 686 - 689
[37] The Utilities of Estrogen Receptor, Cytokeratin 5/6, and Cytokeratin 903 to Differentiate Between Usual Ductal Hyperplasia, Flat Epithelial Atypia, Atypical Ductal Hyperplasia, Ductal Carcinoma In Situ, and Lobular Carcinoma In Situ
Wei, Eric
Dela Cruz, Nestor
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 149 : S30 - S30
[38] Update on ductal carcinoma in situ trials
Julien, JP
Henri, C
EUROPEAN JOURNAL OF CANCER, 1997, 33 : 290 - 290
[39] Effects of reproductive risk factors for ductal carcinoma in situ, invasive ductal carcinoma, and invasive ductal carcinoma with ductal carcinoma in situ on clinical outcomes
Lee, J.
Lee, J.
Oh, M.
CANCER RESEARCH, 2016, 76
[40] The role of clinical trials in changing therapy for ductal carcinoma in situ
Wood, WC
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (01) : 24S - 27S

← 1 2 3 4 5 →